奥希替尼耐药后EGFR突变肺癌的新兴治疗范式综述
奥希替尼自2018年4月获批后广泛用于晚期EGFR突变NSCLC一线治疗,本综述基于6项奥希替尼耐药系列数据,描述EGFR依赖与非依赖耐药机制的异质性,并提供循证算法化评估管理路径及在研临床试验汇编。
要点
- 奥希替尼一线进展后需明确耐药机制以选择二线治疗。
- 常见耐药机制包括MET改变、EGFR C797X、SCLC转化和致癌基因融合。
- 综述提供算法化评估管理路径及活跃临床试验汇编。
核心结论
- 奥希替尼一线进展后应基于耐药机制选择个体化二线治疗。
研究设计与样本
- 综述,汇总6项奥希替尼耐药系列数据。
主要发现
- MET改变发生率为7%-24%。
- EGFR C797X发生率为0%-29%。
- SCLC转化发生率为2%-15%。
- 致癌基因融合发生率为1%-10%。
关键数值与推荐
- MET改变、EGFR C797X、SCLC转化和致癌基因融合是最常见的耐药机制。
临床怎么用
- 采用循证算法化路径评估和管理奥希替尼进展后患者。
- 参考活跃临床试验汇编为患者选择在研治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC). Understanding osimertinib resistance mechanisms and currently available treatment options are essential to selecting optimal second line therapy for patients whose disease progresses during front-line osimertinib. Using data compiled from 6 osimertinib-resistance series, we describe here the heterogeneous profile of EGFR-dependent and independent mechanisms of osimertinib treatment failure. We identified MET alterations (7%-24%), EGFR C797X (0%-29%), SCLC transformation (2%-15%), and oncogene fusions (1%-10%) as the most common mechanisms of resistance. This review provides an evidence-based, algorithmic approach to the evaluation and management of post-osimertinib progression as well as a compendium of active, enrolling clinical trials for this population.
引用
- Piper-Vallillo AJ, Sequist LV, Piotrowska Z, et al. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. J Clin Oncol. 2020. PMID: 32552277. doi:10.1200/JCO.19.03123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。